Gain Therapeutics Inc. (GANX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy
Does Gain Therapeutics, Inc. (GANX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients
Gain Therapeutics achieved functional improvement in Parkinson's patients with GT-02287 in its Phase 1b trial, notably improving MDS-UPDRS Part III motor scores. GT-02287's mechanism addresses GCase misfolding earlier in the disease process, potentially offering superior efficacy versus competitors. GANX's $66 million market cap is seen as deeply undervalued given positive trial data, large market potential, and higher-value biotech acquisitions.
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results
Gain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson's disease, with potential for substantial market impact and investor gains. The drug's ability to restore GCase function and its positive preclinical and Phase 1 results highlight its potential as a best-in-class treatment. Gain's aggressive development strategy and strong data sharing indicate confidence, with Phase 1b trial results expected by mid-2025, potentially increasing the company's valuation.
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Gain Therapeutics (GANX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Gain Therapeutics, Inc. (GANX) Special Call Transcript
Gain Therapeutics, Inc. (NASDAQ:GANX ) Special Call Transcript July 1, 2024 8:30 AM ET Company Participants Apaar Jammu - Manager, Investor Relations Gene Mack - Chief Financial Officer & Interim Chief Executive Officer Conference Call Participants Operator Hello, all. Thank you for joining us today for Gain Therapeutics Corporate and Business Update Call.
Why Is Gain Therapeutics (GANX) Stock Down 25% Today?
Gain Therapeutics (NASDAQ: GANX ) stock is falling on Friday following the pricing of its shares in a public offering. This public offering has Gain Therapeutics selling 7,116,547 shares and pre-funded warrants for 1,031,602 shares.
Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential
Gain Therapeutics, Inc.'s drug candidate GT-02287 has best-in-class potential to slow or stop disease progression in Parkinson's disease. Gain is progressing at an impressive speed through its Phase 1 trial. Drug discovery engine Magellan, which had already generated a Phase 3 drug in the past, may be overlooked by investors.
